Table 1.

Treatment sequences received by patients with docetaxel as first observed mCRPC therapy

	n (%)
Sequence of two therapies
Docetaxel → AR-targeted therapy	365 (81.8)
Abiraterone	233 (52.2)
Enzalutamide	129 (28.9)
Abiraterone/enzalutamide	3 (0.7)
Docetaxel → cabazitaxel	69 (15.5)
Other (e.g., cabazitaxel/AR-targeted therapy)	12 (2.7)
Total patients with a sequence of two therapies	446 (69.0)
Sequence of three therapies
Docetaxel → AR-targeted therapy → alternative AR-targeted therapy	57 (37.5)
Abiraterone → enzalutamide	40 (26.3)
Enzalutamide → abiraterone	15 (9.9)
Abiraterone → abiraterone/enzalutamide	2 (1.3)
Docetaxel → AR-targeted therapy → chemotherapy	44 (28.9)
Abiraterone → cabazitaxel	20 (13.2)
Enzalutamide → cabazitaxel	13 (8.6)
Abiraterone → docetaxel	6 (3.9)
Enzalutamide → docetaxel	5 (3.3)
Docetaxel → AR-targeted therapy → other (e.g., chemotherapy/alternative AR-targeted therapy)	3 (2.0)
Docetaxel → cabazitaxel → AR-targeted therapy	42 (27.6)
Cabazitaxel → abiraterone	28 (18.4)
Cabazitaxel → enzalutamide	14 (9.2)
Docetaxel → cabazitaxel → other (e.g., chemotherapy/AR-targeted therapy)	1 (0.7)
Other (e.g., chemotherapy/AR-targeted therapy)	5 (3.3)
Total patients with a sequence of three therapies	152 (23.5)
Sequence of four or more therapies
Total patients with a sequence of four therapies	37 (5.7)
Total patients with a sequence of five therapies	8 (1.2)
Total patients with a sequence of six therapies	3 (0.5)
Total	646 (100)
Patients with second-line cabazitaxel or AR-targeted therapy	629 (97.4)

AR androgen receptor, mCRPC metastatic castration-resistant prostate cancer